| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Original articles |
Consensus meeting for the management of gastrointestinal stromal tumors
Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO
* Correspondence to: Dr J.-Y. Blay, Unité INSERM 590, Centre Léon Bérard, 69008 Lyon and Hopital Edouard Herriot, Place d'Arsonval, 69003 Lyon, France. Tel: +33-4-78-78-51-09; Fax: +33-4-78-78-27-14; Email: blay{at}iyon.fnclcc.fr and; Email: jean-yves.blay{at}chu-lyon.fr
Background: The management of gastrointestinal stromal tumors (GIST) has evolved very rapidly in the last 4 years. The objectives of this international consensus meeting were to describe the optimal management procedures for patients with GIST in localized and advanced stages, as well as research issues for the future.
Materials and methods: A panel of experts from six specialties, including pathology, molecular biology, imaging, surgery, medical oncology and methodologists for clinical practice guidelines from different European and extra European sarcoma societies were invited to a 2-day workshop. Several questions were selected by the organizing committee prior to the conference. Selected panelists reviewed the current levels of evidence for each point, and presented their conclusions during the meeting. These proposals were discussed, and consensus points were identified and categorized according to the Standard Options Recommandations (SOR) of the French Federation of Cancer Centers and National Comprehensive Cancer Network (NCCN).
Results: Thirty-two consensus points were identified, most from categories 2A of the NCCN and B2 of the SOR. Among these, the standard histological examination with immunohistochemical analysis using CD117, CD34, PS100, desmin and smooth muscle actin is considered standard. Molecular biology for the identification of KIT and PDGFRA mutation is an optional diagnostic procedure for GIST with negative CD117 staining, and otherwise is considered a research procedure. Complete tumor resection with negative tumor margins is the standard surgical treatment. Adjuvant imatinib after optimal tumor resection as well as neo-adjuvant imatinib remain experimental approaches to be performed within prospective clinical studies. Imatinib should be started at the date of diagnosis of metastatic relapse and given until development of intolerance or progressive disease. The optimal criteria for tumor response to imatinib remain to be delineated, and should include not only tumor size reduction or disease stabilization, but also reduction of tumor density (Hounsfield Units) on computed tomography and metabolic activity (i.e. reduction of FDG uptake on positron emission tomography). In a substantial proportion of patients, stable disease and even increase in tumor size may be associated with pathologic response to imatinib therapy, and available survival data indicate that the survival of these patients is similar to that of patients with conventional tumor response. Metastasis resection is an experimental procedure.
Conclusions: Consensus points in clinical management of GIST as well as questions for future clinical trials were identified during this consensus conference on GIST management.
Key words: consensus, ESMO, GIST, imatinib
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Mussi, H.-U. Schildhaus, A. Gronchi, E. Wardelmann, and P. Hohenberger Therapeutic Consequences from Molecular Biology for Gastrointestinal Stromal Tumor Patients Affected by Neurofibromatosis Type 1 Clin. Cancer Res., July 15, 2008; 14(14): 4550 - 4555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Yan, G. G. Kaplan, S. Urbanski, C. L. Nash, and P. L. Beck Epidemiology of Gastrointestinal Stromal Tumors in a Defined Canadian Health Region: A Population-Based Study International Journal of Surgical Pathology, July 1, 2008; 16(3): 241 - 250. [Abstract] [PDF]
|
|
|
|
 |
|
 D. R. Lucas, M. P. Kshirsagar, J. S. Biermann, M. R. Hamre, D. G. Thomas, S. M. Schuetze, and L. H. Baker Histologic Alterations from Neoadjuvant Chemotherapy in High-Grade Extremity Soft Tissue Sarcoma: Clinicopathological Correlation Oncologist, April 1, 2008; 13(4): 451 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Showalter, J. M. Lloyd, D. T. Glassman, and A. C. Berger Extra-Gastrointestinal Stromal Tumor of the Pancreas: Case Report and a Review of the Literature Arch Surg, March 1, 2008; 143(3): 305 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A L Gomes, A Gouveia, A F Capelinha, D de la Cruz, P Silva, R M Reis, A Pimenta, and J M Lopes Molecular alterations of KIT and PDGFRA in GISTs: evaluation of a Portuguese series J. Clin. Pathol., February 1, 2008; 61(2): 203 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Cassier, A. Dufresne, and J.-Y. Blay Controversies in the Adjuvant Treatment of Gastrointestinal Stromal Tumors (GIST) with Imatinib ASCO Educational Book, January 1, 2008; 2008(1): 524 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Masuda, Y. Toh, A. Kabashima, Y. Aoki, N. Harimoto, S. Ito, J. Taomoto, O. Ikeda, T. Ohga, E. Adachi, et al. Overt lymph node metastases from a gastrointestinal stromal tumor of the esophagus J. Thorac. Cardiovasc. Surg., September 1, 2007; 134(3): 810 - 811. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zamo, A. Bertolaso, I. Franceschetti, G. Weirich, P. Capelli, S. Pecori, M. Chilosi, H. Hoefler, F. Menestrina, and A. Scarpa Microfluidic Deletion/Insertion Analysis for Rapid Screening of KIT and PDGFRA Mutations in CD117-Positive Gastrointestinal Stromal Tumors: Diagnostic Applications and Report of a New KIT Mutation J. Mol. Diagn., April 1, 2007; 9(2): 151 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Blay, A. Le Cesne, I. Ray-Coquard, B. Bui, F. Duffaud, C. Delbaldo, A. Adenis, P. Viens, M. Rios, E. Bompas, et al. Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group J. Clin. Oncol., March 20, 2007; 25(9): 1107 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Haller, S. Detken, H.-J. Schulten, N. Happel, B. Gunawan, J. Kuhlgatz, and L. Fuzesi Surgical Management After Neoadjuvant Imatinib Therapy in Gastrointestinal Stromal Tumours (GISTs) with Respect to Imatinib Resistance Caused by Secondary KIT Mutations Ann. Surg. Oncol., February 1, 2007; 14(2): 526 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bonvalot, H. Eldweny, C. Le Pechoux, D. Vanel, P. Terrier, A. Cavalcanti, C. Robert, N. Lassau, and A. Le Cesne Impact of Surgery on Advanced Gastrointestinal Stromal Tumors (GIST) in the Imatinib Era Ann. Surg. Oncol., December 1, 2006; 13(12): 1596 - 1603. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Tornillo and L M Terracciano An update on molecular genetics of gastrointestinal stromal tumours. J. Clin. Pathol., June 1, 2006; 59(6): 557 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Salazar, A Barata, S Andre, J Venancio, I Francisco, M Cravo, and C Nobre-Leitao First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy. Gut, April 1, 2006; 55(4): 585 - 586. [Full Text] [PDF]
|
|
|
|
 |
|
 A Saleem Potential of PET in oncology and radiotherapy Br. J. Radiol., November 1, 2005; Supplement_28(1): 6 - 16. [Full Text] [PDF]
|
|